Want to see OCUL full AI Analyst Report?
OCUL Stock Chart & Stats
$10.88
-$0.11(-1.33%)
At close: 4:00 PM EDT
$10.88
-$0.11(-1.33%)
Day’s Range― - ―
52-Week Range$6.00 - $16.44
Previous CloseN/A
Volume1.17M
Average Volume (3M)3.68M
Market Cap
$1.42B
Enterprise Value$1.69B
Total Cash (Recent Filing)$598.64M
Total Debt (Recent Filing)$79.38M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Nov 09, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding219,615,880
10 Day Avg. Volume3,572,391
30 Day Avg. Volume3,678,684
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)3.47
Price to Sales (P/S)43.86
P/FCF Ratio-10.48
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue32.46
Enterprise Value/Gross Profit37.26
Enterprise Value/Ebitda-5.94
Forecast
1Y Price Target
$24.13Price Target Upside121.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.5
Revenue Forecast (FY)$52.77M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsConsistently high gross margins indicate that Ocular Therapeutix’s products and technology can generate substantial value after direct costs. This provides a solid economic foundation for future scale, although operating discipline and sufficient revenue growth are still needed to convert gross profit into sustainable earnings.
Manageable LeverageImproved leverage and a sizable asset and equity base provide greater financial flexibility than the company had in earlier periods. This can support continued development and commercialization efforts, while reducing balance-sheet pressure as management works to improve profitability and cash generation.
Specialized Ophthalmic PlatformA focused ophthalmic platform built around bioresorbable hydrogel delivery gives Ocular Therapeutix a differentiated basis for developing therapies that improve dosing convenience and clinical outcomes. This specialization can support product expansion and strategic relevance across multiple eye-disease indications.
Bears Say
Worsening Operating LossesWorsening operating losses show that the company is not yet converting its strong gross margins into sustainable earnings. Continued losses can constrain investment choices, increase dependence on external financing, and make it harder to fund pipeline development without shareholder dilution.
Persistent Cash BurnPersistent negative operating and free cash flow means the business currently lacks self-funding capacity. If cash outflows remain elevated, Ocular Therapeutix may need additional financing to sustain development and commercialization, increasing funding risk and potentially limiting strategic flexibility.
Leadership Continuity RiskThe departure of the executive responsible for shaping long-term strategy creates a leadership continuity risk during an important development and commercialization phase. A replacement or transition process may affect strategic execution, corporate planning, and confidence in management consistency over the coming quarters.
Ocular Therapeutix News
OCUL FAQ
What was Ocular Therapeutix’s price range in the past 12 months?
Ocular Therapeutix lowest stock price was $6.00 and its highest was $16.44 in the past 12 months.
What is Ocular Therapeutix’s market cap?
Ocular Therapeutix’s market cap is $1.42B.
When is Ocular Therapeutix’s upcoming earnings report date?
Ocular Therapeutix’s upcoming earnings report date is Nov 09, 2026 which is in 18 days.
How were Ocular Therapeutix’s earnings last quarter?
Ocular Therapeutix released its earnings results on Aug 03, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.395 by $0.045.
Is Ocular Therapeutix overvalued?
According to Wall Street analysts Ocular Therapeutix’s price is currently Undervalued.
Does Ocular Therapeutix pay dividends?
Ocular Therapeutix does not currently pay dividends.
What is Ocular Therapeutix’s EPS estimate?
Ocular Therapeutix’s EPS estimate is -0.37.
How many shares outstanding does Ocular Therapeutix have?
Ocular Therapeutix has 219,615,880 shares outstanding.
What happened to Ocular Therapeutix’s price movement after its last earnings report?
Ocular Therapeutix reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.395. Following the earnings report the stock price went up 2.815%.
Which hedge fund is a major shareholder of Ocular Therapeutix?
Currently, no hedge funds are holding shares in OCUL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocular Therapeutix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.13 (121.74% Upside)
$24.13 (121.74% Upside)
Blogger Sentiment
Bullish
OCUL Sentiment 63%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 51.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $253.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.94%
12-Months-Change
Fundamentals
Return on Equity
-59.87%
Trailing 12-Months
Asset Growth
48.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
OCUL Stock 12 Month Forecast
Average Price Target
$24.13
▲(121.74% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
RegenXBio
―
Tarsus Pharmaceuticals
―
Oculis Holding
―
Aura Biosciences Inc
―
Ownership Overview
2.72% Insiders
20.37% Mutual Funds
1.26% Other Institutional Investors
63.26% Public Companies and
Individual Investors